eligibility_summary
Adults (≥18) with relapsed/refractory DLBCL, primary mediastinal B‑cell lymphoma, or transformed FL, eligible for anti‑CD19 CAR‑T, with pre‑CAR‑T PET‑CT, informed consent, and health insurance. Exclude pregnancy/breastfeeding, inadequate FFPE tissue for NGS, lack of consent, CAR‑T in another trial, weight <30 kg, legally protected/incarcerated, or unable to understand/comply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Real-time liquid biopsy monitoring of circulating tumor DNA (ctDNA) by next-generation sequencing after anti-CD19 CAR-T therapy, a diagnostic/monitoring approach to deliver molecular MRD results ~7 days post-infusion (by day 28) to guide management. Therapies administered (standard of care): anti-CD19 CAR-T products axi-cel, tisa-cel, or liso-cel (autologous, genetically engineered T-cell immunotherapies). Mechanism: CAR-T cells recognize CD19 on B-cell lymphomas and, via CAR signaling (CD3ζ plus costimulation, axi-cel uses CD28, tisa-cel/liso-cel use 4-1BB), trigger T-cell activation, cytotoxic killing, and cytokine release to clear malignant B cells. Cells/pathways targeted: CD19-expressing DLBCL B cells, T-cell activation/cytotoxic pathways. Monitoring targets tumor-specific genomic mutations in plasma ctDNA to quantify minimal residual disease.